University of Edinburgh researchers are to work with Belgian clinical stage biotech company Galapagos NV to develop cancer therapies.
A team from the Edinburgh Cancer Research Centre will offer Galapagos access to a wide range of advanced cancer models and technology platforms that provide critical insights into the mechanism of action of particular compounds.
This information will help inform the selection of compounds for clinical development and for improving the effectiveness of those compounds in combating various forms of cancer in patients.
The two-year partnership agreement between Galapagos and the University’s Edinburgh Cancer Research Centre was facilitated by Edinburgh Bioquarter.
The collaboration follows a similar commercial agreement between Glaxosmithkline (GSK) and University medical researchers, secured by Bioquarter in October 2011.
This new partnership with Galapagos demonstrates industry’s growing awareness of the depth of world-class research being undertaken here at Edinburgh. It’s also further evidence of the strength of partnership we enjoy with both the University of Edinburgh’s research community and the bio-pharmaceutical industry.
Commercialisation, Edinburgh Bioquarter
This article was published on Jun 25, 2012